Company profile
Knight Therapeutics Inc.
OTC: KHTRF · Healthcare · Medical - Pharmaceuticals
Canadian filerHQ Montreal, QCReports USD
#242 of 1,418 Healthcare companies by revenue64th-percentile growth
EA Score
77B+FH 79DQ —GM 71SS 73
v0.1 · 45/100 weight · provisional
↑ Piotroski F, growth stability · ↓ disclosure history, listing tenure
Methodology →Revenue TTM
$396.4M
Rev growth YoY (TTM)
+43.7%
Net income (FY)
-$3.8M
Employees
830
as of 2026-08-11
Market cap
$681.4M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$321.7M449.7M CAD2025
Net income-$3.8M-5.4M CAD2025
Operating income-$1.6M-2.2M CAD2025
Total assets$762.8M1.0B CAD2025
Liabilities$203.4M278.8M CAD2025
Equity$559.4M766.6M CAD2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Knight Therapeutics Inc.’s revenue?
Knight Therapeutics Inc. booked $321.7M in FY2025 revenue, growing 19% year over year — faster than most Healthcare companies we track, at a -1.2% net margin.
Peers · Healthcare
Tactile Systems Technology, Inc.83B+Fulgent Genetics, Inc.68BDocGo Inc.44DEagle Pharmaceuticals, Inc.——CorMedix Inc.75B+Health Catalyst, Inc.56CKey facts
CEOSamira Sakhia
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersMontreal, QC
ExchangeOTC: KHTRF
Employees830
IPO date2014-04-03
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.